We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
-0.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$43.7M
Cap. Flow
+$49.2M
Cap. Flow %
33.95%
Top 10 Hldgs %
24.02%
Holding
223
New
58
Increased
36
Reduced
83
Closed
14

Top Buys

Rank Stock Value
1
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$6.28M
2
CNC icon
Centene
CNC
+$3.55M
3
HRMY icon
Harmony Biosciences
HRMY
+$3.07M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.84M
5
QQQ icon
Invesco QQQ Trust
QQQ
+$2.58M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.42M
2
PFSI icon
PennyMac Financial
PFSI
+$1.76M
3
AIRS icon
AirSculpt Technologies
AIRS
+$1.33M
4
STWD icon
Starwood Property Trust
STWD
+$1.19M
5
AME icon
Ametek
AME
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 56.03%
2 Real Estate 10.47%
3 Financials 4.37%
4 Energy 4.28%
5 Technology 3.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNPS icon
51
Synopsys
SNPS
$73.6B
$966K 0.67%
+2,500
New +$893K
ACAD icon
52
Acadia Pharmaceuticals
ACAD
$4.38B
$941K 0.65%
50,000
– –
AGNC icon
53
AGNC Investment
AGNC
$12.9B
$935K 0.65%
92,746
– –
KPTI icon
54
Karyopharm Therapeutics
KPTI
$216M
$934K 0.64%
+16,000
New +$790K
VRDN icon
55
Viridian Therapeutics
VRDN
$1.99B
$903K 0.62%
35,500
– –
KNSA icon
56
Kiniksa Pharmaceuticals
KNSA
$4.92B
$888K 0.61%
82,500
+37,500
+83% +$494K
OMCL icon
57
Omnicell
OMCL
$2.09B
$880K 0.61%
15,000
– –
INMD icon
58
InMode
INMD
$889M
$863K 0.6%
27,000
+17,000
+170% +$582K
ITOS
59
DELISTED
iTeos Therapeutics
ITOS
$857K 0.59%
+63,000
New +$1.13M
AUPH icon
60
Aurinia Pharmaceuticals
AUPH
$2.05B
$849K 0.59%
77,500
-275,000
-78% -$2.42M
WELL icon
61
Welltower
WELL
$172B
$793K 0.55%
11,059
– –
TARO
62
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$790K 0.55%
32,500
+5,000
+18% +$146K
UTHR icon
63
United Therapeutics
UTHR
$22.7B
$784K 0.54%
3,500
+1,250
+56% +$308K
AMRN
64
Amarin Corp
AMRN
$292M
$750K 0.52%
25,000
– –
BTAI icon
65
BioXcel Therapeutics
BTAI
$27.4M
$746K 0.52%
2,500
-625
-20% -$267K
MOR
66
DELISTED
MorphoSys AG American Depositary Shares
MOR
$731K 0.5%
185,000
– –
MTG icon
67
MGIC Investment
MTG
$6.23B
$723K 0.5%
53,900
– –
NNDM
68
Nano Dimension
NNDM
$326M
$723K 0.5%
+250,000
New +$672K
NLY icon
69
Annaly Capital Management
NLY
$16.9B
$717K 0.49%
37,500
– –
GILD icon
70
Gilead Sciences
GILD
$167B
$705K 0.49%
8,500
– –
BBJP icon
71
JPMorgan BetaBuilders Japan ETF
BBJP
$17.1B
$673K 0.46%
+13,912
New +$653K
EXEL icon
72
Exelixis
EXEL
$14.1B
$641K 0.44%
33,000
– –
DPRO
73
Draganfly
DPRO
$155M
$640K 0.44%
20,000
+8,000
+67% +$330K
MPC icon
74
Marathon Petroleum
MPC
$91.3B
$621K 0.43%
4,609
-210
-4% -$26.3K
SLGC
75
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$611K 0.42%
239,500
-175,500
-42% -$503K
1 2
3
4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, AlphaCentric Advisors held 223 positions worth $145M, up 43% from $101M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

AlphaCentric Advisors deployed $49.2M of net new capital in Q1 2023, opening 58 new positions and adding to 36 existing holdings. Its largest new stake was iShares 1-3 Year Treasury Bond ETF: 76,992 shares worth $6.33M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 57% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $2.42M trimmed.

  • AlphaCentric Advisors's largest Q1 2023 buy was iShares 1-3 Year Treasury Bond ETF: 76,992 shares worth $6.33M.
  • AlphaCentric Advisors added most to BioCryst Pharmaceuticals in Q1 2023, an estimated $2.84M increase.
  • AlphaCentric Advisors's biggest Q1 2023 reduction was Aurinia Pharmaceuticals, cutting an estimated $2.42M.
  • AlphaCentric Advisors fully exited PennyMac Financial in Q1 2023, selling an estimated $1.76M.
  • AlphaCentric Advisors's ten largest holdings make up 24% of its $145M portfolio in Q1 2023.
  • AlphaCentric Advisors opened 58 new positions and closed 14 in Q1 2023.
  • AlphaCentric Advisors's portfolio value rose 43% quarter-over-quarter to $145M.

Based on AlphaCentric Advisors's 13F filing for Q1 2023, filed 12 May 2023.